Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults

Core Insights - Ardelyx, Inc. presented new clinical data on IBSRELA® (tenapanor) at the 2024 Digestive Disease Week Conference, highlighting its safety and efficacy for treating irritable bowel syndrome with constipation (IBS-C) in adults [1][2] - The data includes a post hoc analysis from the Phase 3 T3MPO-1 and T3MPO-2 studies, showing clinically meaningful responses to tenapanor regardless of prior medication use [2] - Efficacy of tenapanor was found to be comparable or more pronounced in Hispanic patients compared to non-Hispanic patients [3] Company Overview - Ardelyx is focused on discovering, developing, and commercializing innovative medicines to address significant unmet medical needs [1][12] - The company has two commercial products approved in the U.S.: IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) [12] - Ardelyx has international agreements for the development and commercialization of tenapanor, including partnerships in Japan and Canada [12] Product Information - IBSRELA (tenapanor) is a first-in-class treatment approved by the FDA for IBS-C in adults, acting as a sodium/hydrogen exchanger 3 (NHE3) inhibitor [1][4] - The mechanism of action involves reducing sodium absorption in the intestines, which helps retain water and improve stool consistency [4] - IBS-C affects an estimated 12 million people in the U.S., leading to impaired quality of life and economic burden [5]